The Company
L3 Technology Limited (L3T) was founded in 2002 to commercialise lipid detection technology originating from the Daresbury Laboratory of the Council for the Central Laboratory of the Research Councils (CCLRC) of the United Kingdom. In April 2007, CCLRC became a part of the Science and Technology Facilities Council (STFC).
The intellectual property and know-how acquired from STFC forms the foundation of the core lipid measurement technology used in the L3T Lipid Profile assays. This technology uses specific dyes, which when added directly to lipid solutions combine with specific fractions and sub-species of cholesterol. Dye / Lipid complexes fluoresce and the intensity of this fluorescence quantifies the amount of each fraction present in the sample. Throughout the development process L3T has strengthened its extensive intellectual property portfolio and know how.
In 2005, L3T began its programme to exploit the opportunities for growth in the point of care (POC) testing segment and adapt its lipid testing technology to a format suitable for situations when delivering results with the patient present, is important or beneficial.
Whilst transferring the chemistry to a dried phase on a disposable card, L3T developed a highly cost-effective mechanism to enhance sample flow. This invention is now the subject of a patent on a worldwide basis. Refer to Enabling Technology for further information.
The L3T POC system utilises room temperature stable dried reagents, a unique disposable card technology, a solution to control lateral flow and a hand held fluorescence card reader. Development of this platform, coupled with the Company’s broad technology and know-how, means that other tests required in point of care situations can be adapted for this reliable system. Further opportunities for this system are discussed in Potential Applications section.
L3T is now conducting clinical evaluations of its prototype lipid testing system and has other tests in development.
L3T uses development partners to manufacture disposable cards and to design and develop the fluorescence reader for the L3T Reagent Card.
L3T is a privately held company, which is supported principally by:
 |
 |
 |
 |
 |
 |